Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00872_DB00921_nanopub.RAte0jfDi4PdqUnuLc7ZVwPcOWJaGchzcEv22wFN2O1Kk#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00872_DB00921 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00872_DB00921 label "DDI between Conivaptan and Buprenorphine - Conivaptan may increase the serum concentration of CYP3A4 Substrates like buprenorphine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. [drugbank_resource:DB00872_DB00921]" assertion.
- drugbank_resource:DB00872_DB00921 identifier "drugbank_resource:DB00872_DB00921" assertion.
- drugbank_resource:DB00872_DB00921 title "DDI between Conivaptan and Buprenorphine - Conivaptan may increase the serum concentration of CYP3A4 Substrates like buprenorphine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates." assertion.
- drugbank:DB00872 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00872_DB00921 assertion.
- drugbank:DB00921 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00872_DB00921 assertion.